SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS
https://doi.org/10.20996/1819-6446-2011-7-4-442-446
Abstract
Aim. To study the relations of clinical characteristics and individual warfarin dose titration in patients with atrial fibrillation. Material and methods. Period of warfarin dose titration was analyzed in 68 patients with atrial fibrillation due to ischemic heart disease. Adjusted warfarin dose in milligram, duration of dose titration in days and maximal international normalized ratio (INR) were taken into account. Sex, age, history of myocardial infarction and stroke, concomitant diseases, amiodarone therapy were considered among clinical characteristics. Results. Adjusted warfarin dose was significantly higher in obesity , and it was lower in case of experienced myocardial infarction. The INR highest levels and maximal amplitudes of its fluctuations were observed in patients with thyroid gland nodes and smokers. Period of warfarin dose titration was longer in patients treated with amiodarone. Conclusion. Warfarin dose titration in patients with atrial fibrillation depends on the presence of myocardial infarction, obesity , thyroid nodular changes, smoking and amiodarone treatment.
About the Authors
E. L. Artanova
Saratov State Medical University
Russian Federation
Russian Federation
E. V. Saleeva
Saratov State Medical University
Russian Federation
Russian Federation
I. M. Sokolov
Saratov State Medical University
Russian Federation
Russian Federation
Y. G. Shvarts
Saratov State Medical University
Russian Federation
Russian Federation
References
1. Hirsh J., Fuster V., Ansell J., Halperin J.L. AMA/American College of Cardilogy Foundation guide to War-farin therapy. J Am Coll Cardiol 2003; 41:1633–1652.
2. Hylek E.M., Chang Y., Jensvold N.G. et al Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med 2003; 349: 1019–1026.
3. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J 2001:22:1852-1923.
4. Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26(22):2422-34.
5. National guidelines for diagnosis and treatment of atrial fibrillation. Kardiovaskuljarnaja terapija i pro-filaktika 2005; 4(4) Prilozhenie 1; 1-42). Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий. Кардиоваскулярная терапия и профилактика 2005; 4(4) Приложение 1; 1-42).
6. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527-39.
7. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361(12):1139-1151.
8. Zaridze D.G., Karpov R.S., Kiseleva S.M. et al. Smoking — the main reason for high mortality of Russians. Vestnik RAMN 2002; 9: 40-45. Russian (Заридзе Д.Г., Карпов Р.С., Киселева С.М. и др. Курение — основная причина высокой смертности россиян. Вестник РАМН 2002;9:40-45).
9. Ostroumova O.D., Batutina A.M., Zykova A.A. Drug interactions: Are there any"ideal" drugs for use in polypharmacy? Russkij medicinskij zhurnal 2003;11(21): 1152-1167. Russian (Остроумова О.Д., Батутина А.М., Зыкова А.А. Лекарственное взаимодействие: существуют ли "идеальные" лекарственные препараты для использования в условиях полипрагмазии? Русский медицинский журнал 2003;11(21): 1152-1167).
10. Martinelli N., Trabetti E., Pinotti M. et al. Combined Effect of Hemostatic Gene Polymorphisms and the Risk of Myocardial Infarction in Patients with Advanced Coronary Atherosclerosis. PLoS ONE 2008; 3(2): e1523.
11. van der Krabben M.D., Rosendaal F.R., van der Bom J.G., Doggen C.J. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 2008;6(5):717-9.
12. Alpert J.S., Thygesen K., Antman E., Bassand J.P. Myocardial infarction redefined — a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36(3):959-69.
13. Belousov D.Ju., Mednikov O.I. Need and use of antiplatelet drugs in patients with myocardial infarction. Russian (Kachestvennaja klinicheskaja praktika 2003;1:60-70. Белоусов Д.Ю., Медников О.И. Потребность и использование антитромбоцитарных препаратов у больных, перенесших инфаркт миокарда. Качественная клиническая практика 2003;1:60-70).
14. Busenbark L.A., Cushnie S.A. Effect of Graves' disease and methimazole on warfarin anticoagulation. Ann Pharmacother 2006; 40: 1200-1203.
15. Takeuchi F., Kashida M., Okazaki O. et al. Evaluation of Pharmacogenetic Algorithm for Warfarin Dose. Requirements in Japanese Patients. Circulation 2010; 74: 977-982.
Review
For citations:
Artanova E.L., Saleeva E.V., Sokolov I.M., Shvarts Y.G. SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS. Rational Pharmacotherapy in Cardiology. 2011;7(4):442-446. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-4-442-446
Views: 604
Email this article 